Efficacy and prognostic analysiss of rituximab in the treatment of M-type phospholipase A2 receptor-associated idiopathic membranous nephropathy  

作　　者：CHEN Jia 陈嘉(Dept Nephrol,Shenzhen 2nd People's Hosp,Shenzhen 518000)

机构地区：[1]Dept Nephrol,Shenzhen 2nd People's Hosp,Shenzhen 518000

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第4期225-226,共2页中国医学文摘(内科学分册英文版)

摘　　要：Objective To investigate the efficacy and prognosis of rituximab(RTX)in the treatment of M-type phospholipase A2 receptor(PLA2R)-associated idiopathic membranous nephropathy(IMN).Methods It was a retrospective cohort study.The clinical data of PLA2Rassociated IMN patients who received RTX treatment in the Shenzhen Second People's Hospital from September 2018 to March 2023 were collected.

关 键 词：MEMBRANOUS NEPHROPATHY TREATMENT 

分 类 号：R69[医药卫生—泌尿科学]